Quick answers
- What is Apixaban used for?
- The FDA-approved label (Eliquis, Cardinal Health 107, LLC, April 24, 2026) says: “ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Apixaban have a boxed warning?
- Yes. The FDA label for Eliquis has a boxed warning, the FDA’s strongest warning. Read it on the full label and ask your pharmacist.
- Is there a shortage of Apixaban?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Apixaban been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started June 5, 2017 (Class I). A recall usually concerns specific lots, not every product.
- Who makes Apixaban?
- 8 companies list prescription products of Apixaban in the FDA NDC Directory, including E.R. Squibb & Sons, L.L.C., A-S Medication Solutions and Amneal Pharmaceuticals of New York LLC.
What Apixaban is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. …
— FDA label: Eliquis, Cardinal Health 107, LLC, effective April 24, 2026. Read the full label on DailyMed →
The FDA has 8 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
This label has a boxed warning. Read it on the full label →
8 of 8 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet, film coated · Tablet, for suspension · Capsule |
|---|---|
| Route | Oral |
| Prescription products | 18 in the FDA NDC Directory |
| Brand names | Eliquis, Eliquis Sprinkle |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| apixaban 2.5 mg tablet, film coated | Brand: Eliquis | $5.51 per tablet |
| apixaban 5 mg tablet, film coated | Brand: Eliquis | $5.52 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- E.R. Squibb & Sons, L.L.C.4 products
- A-S Medication Solutions4 products
- Amneal Pharmaceuticals of New York LLC2 products
- Cardinal Health 107, LLC2 products
- Indoco Remedies Limited2 products
- Aphena Pharma Solutions - Tennessee, LLC2 products
- Remedyrepack Inc.1 product
- Proficient Rx LP1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA202155 ELIQUIS | Bristol Myers Squibb | December 28, 2012 | 24, latest June 24, 2026 2026: Labeling · 2025: Efficacy · 2025: Efficacy |
| NDA220073 ELIQUIS, ELIQUIS SPRINKLE | Bristol | April 17, 2025 | 1, latest June 24, 2026 2026: Labeling |
Generic approvals (2)
- ANDA209898Regcon Holdings · September 11, 2020
- ANDA209810Impax · February 14, 2025
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
June 5, 2017 · Class I · Terminated · D-0959-2017
Labeling: Label Mix-up: One bottle of Eliquis 5 mg tablet was found to contain lower-strength Eliquis 2.5 mg tablets only instead of the labeled 5 mg tablets.
EliquisTablets 5mg, 60 count bottle, Rx Only, Marketed by: Bristol-Meyers Squibb Company Princeton, NJ 08543 USA and Pfizer Inc. New York, NY 10017 USA, NDC 0003-0894-21 — Bristol-myers Squibb Company
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 1364435, 1364441, 1364445, 1364447 |
|---|---|
| SPL set ID of the quoted label | a454cd24-0c6d-46e8-b1e4-197388606175 |
| FDA labels (SPL) | 8 |
| FDA applications | NDA202155, NDA220073, 2 ANDA |
| Active ingredients (FDA) | APIXABAN |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Eliquis, Cardinal Health 107, LLC, effective April 24, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →